Mereo BioPharma Group (STU:MAH0) Total Assets : €72.95 Mil (As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Mereo BioPharma Group Total Assets?

Mereo BioPharma Group's Total Assets for the quarter that ended in Dec. 2024 was €72.95 Mil.

During the past 12 months, Mereo BioPharma Group's average Total Assets Growth Rate was -27.40% per year. During the past 3 years, the average Total Assets Growth Rate was -46.60% per year. During the past 5 years, the average Total Assets Growth Rate was -43.60% per year.

During the past 10 years, Mereo BioPharma Group's highest 3-Year average Total Assets Growth Rate was 30.90%. The lowest was -53.50%. And the median was -4.90%.

Total Assets is connected with ROA %. Mereo BioPharma Group's annualized ROA % for the quarter that ended in Dec. 2024 was -35.20%. Total Assets is also linked to Revenue through Asset Turnover. Mereo BioPharma Group's Asset Turnover for the quarter that ended in Dec. 2024 was 0.00.

Mereo BioPharma Group Total Assets Historical Data

The historical data trend for Mereo BioPharma Group's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mereo BioPharma Group Total Assets Chart

Mereo BioPharma Group Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Assets

Get a 7-Day Free Trial

70.52

151.00

73.08

60.98

72.95

Mereo BioPharma Group Quarterly Data
	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Assets	Get a 7-Day Free Trial															60.98	51.46	89.30	79.96	72.95

Mereo BioPharma Group Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Mereo BioPharma Group's Total Assets for the fiscal year that ended in Dec. 2024 is calculated as

Total Assets	=	Total Equity (A: Dec. 2024 )	+	Total Liabilities (A: Dec. 2024 )
	=	58.225	+	14.727
	=	72.95

Mereo BioPharma Group's Total Assets for the quarter that ended in Dec. 2024 is calculated as

Total Assets	=	Total Equity (Q: Dec. 2024 )	+	Total Liabilities (Q: Dec. 2024 )
	=	58.225	+	14.727
	=	72.95

Mereo BioPharma Group (STU:MAH0) Total Assets Explanation

Total Assets is connected with ROA %.

Mereo BioPharma Group's annualized ROA % for the quarter that ended in Dec. 2024 is

ROA %	=	Net Income (Q: Dec. 2024 )	/	( (Total Assets (Q: Sep. 2024 )	+	Total Assets (Q: Dec. 2024 ))	/ count )
	=	-26.916	/	( (79.96	+	72.952)	/ 2 )
	=	-26.916	/	76.456
	=	-35.20 %

Note: The Net Income data used here is four times the quarterly (Dec. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Mereo BioPharma Group's Asset Turnover for the quarter that ended in Dec. 2024 is

	Asset Turnover
=	Revenue (Q: Dec. 2024 )	/	( (Total Assets (Q: Sep. 2024 )	+	Total Assets (Q: Dec. 2024 ))	/ count )
=	0	/	( (79.96	+	72.952)	/ 2 )
=	0	/	76.456
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Mereo BioPharma Group Total Assets Related Terms

Thank you for viewing the detailed overview of Mereo BioPharma Group's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Mereo BioPharma Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mereo BioPharma Group PLC (STU:MAH0) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

MREO:USA 0A9G:UK

Address

One Cavendish Place, 4th Floor, London, GBR, W1G 0QF

Website

https://www.mereobiopharma.com

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

Mereo BioPharma Group Headlines

No Headlines